Price$1.50-0.02 (-1.32%)
01:30 PM07:45 PM
News · 26 weeks240%
2025-12-142026-06-07
Mix1490d
- SEC Filings5(36%)
- Insider4(29%)
- Other3(21%)
- Earnings2(14%)
Latest news
25 items- SECPulmonx Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Pulmonx Corp (0001127537) (Filer)
- INSIDERChief Science &Techn. Officer Radhakrishnan Srikanth sold $22,325 worth of shares (14,497 units at $1.54), decreasing direct ownership by 4% to 331,239 units (SEC Form 4) to cover withholding tax4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERGENERAL COUNSEL Lehman David Aaron sold $22,475 worth of shares (14,594 units at $1.54), decreasing direct ownership by 4% to 376,161 units (SEC Form 4) (withholding obligation)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERCHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $12,355 worth of shares (8,023 units at $1.54), decreasing direct ownership by 2% to 457,711 units (SEC Form 4) (for withholding tax)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERPresident and CEO French Glendon E. Iii sold $86,875 worth of shares (56,149 units at $1.55), decreasing direct ownership by 5% to 1,178,162 units (SEC Form 4) (withholding tax)4 - Pulmonx Corp (0001127537) (Issuer)
- PRPulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of t
- SECSEC Form 10-Q filed by Pulmonx Corporation10-Q - Pulmonx Corp (0001127537) (Filer)
- SECPulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmonx Corp (0001127537) (Filer)
- PRPulmonx Reports First Quarter 2026 Financial ResultsREDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first quarter of 2026, representing a 12% year-over-year decrease
- PRPulmonx to Present at the Bank of America Securities 2026 Health Care ConferenceREDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va
- SECSEC Form DEFA14A filed by Pulmonx CorporationDEFA14A - Pulmonx Corp (0001127537) (Filer)
- SECSEC Form DEF 14A filed by Pulmonx CorporationDEF 14A - Pulmonx Corp (0001127537) (Filer)
- PRPulmonx to Report First Quarter 2026 Financial Results on April 29, 2026REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pulmonx CorporationSCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)
- SECSEC Form S-8 filed by Pulmonx CorporationS-8 - Pulmonx Corp (0001127537) (Filer)
- SECSEC Form 10-K filed by Pulmonx Corporation10-K - Pulmonx Corp (0001127537) (Filer)
- INSIDERChief Science &Techn. Officer Radhakrishnan Srikanth sold $14,991 worth of shares (10,483 units at $1.43) and was granted 175,000 shares, increasing direct ownership by 91% to 345,736 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERPresident and CEO French Glendon E. Iii sold $96,973 worth of shares (67,813 units at $1.43), decreasing direct ownership by 5% to 1,409,511 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERCHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $11,057 worth of shares (7,732 units at $1.43) and was granted 100,000 shares, increasing direct ownership by 25% to 465,734 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERGENERAL COUNSEL Lehman David Aaron sold $17,499 worth of shares (12,237 units at $1.43) and was granted 150,000 shares, increasing direct ownership by 54% to 390,755 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- SECPulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmonx Corp (0001127537) (Filer)
- PRPulmonx Reports Fourth Quarter and Full Year 2025 Financial ResultsREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7
- PRPulmonx Announces Closing of up to $60 Million Credit FacilityREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors. The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company's existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027, subject to the achievement of certain revenue milestones. The new facility is interest only until maturity in 2031, and bears interest at a rate equal to one-month Term SOFR (subject to
- PRPulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatmen
- INSIDERNew insider Radhakrishnan Srikanth claimed ownership of 181,219 shares (SEC Form 3)3 - Pulmonx Corp (0001127537) (Issuer)
LUNG FAQ
7 questionsWhat does Pulmonx Corporation do?
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based...Where does LUNG stock trade?
Pulmonx Corporation (LUNG) is listed on NASDAQ.What sector and industry is LUNG in?
Pulmonx Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Pulmonx Corporation go public?
Pulmonx Corporation (LUNG) completed its IPO in 2020.What are analysts saying about LUNG?
Pulmonx Corporation has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Neutral with a $250.00 price target on 2025-07-31.What companies are similar to LUNG?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare LUNG side-by-side with any of them on Quantisnow.How can I track LUNG on Quantisnow?
Quantisnow aggregates Pulmonx Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUNG to receive live email and push alerts on every new disclosure.